Opus Genetics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OPUS GENETICS, INC. | ||
| Dated: March 31, 2025 | By: | /s/ George Magrath |
|---|---|---|
| George Magrath | ||
| Chief Executive Officer and Director | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By | /s/ George Magrath | Date: March 31, 2025 |
|---|---|---|
| George Magrath | ||
| Chief Executive Officer and Director (Principal Executive Officer) | ||
| By | /s/ Nirav Jhaveri | Date: March 31, 2025 |
| Nirav Jhaveri | ||
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||
| By | /s/ Sean Ainsworth | Date: March 31, 2025 |
| Sean Ainsworth | ||
| Director | ||
| By | /s/ Dr. Jean Bennett | Date: March 31, 2025 |
| Dr. Jean Bennett | ||
| Director | ||
| By | /s/ Susan K. Benton | Date: March 31, 2025 |
| Susan K. Benton | ||
| Director | ||
| By | /s/ Cam Gallagher | Date: March 31, 2025 |
| Cam Gallagher | ||
| Director | ||
| By | s/ Dr. Adrienne Graves | Date: March 31, 2025 |
| Dr. Adrienne Graves | ||
| Director | ||
| By | /s/ James S. Manuso | Date: March 31, 2025 |
| James S. Manuso | ||
| Director | ||
| By | /s/ Richard J. Rodgers | Date: March 31, 2025 |
| Richard J. Rodgers | ||
| Director | ||
| By | /s/ Dr. Benjamin R. Yerxa | Date: March 31, 2025 |
| Dr. Benjamin R. Yerxa | ||
| President and Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.